Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Distinct virologic trajectories in chronic hepatitis B identify heterogeneity in response to nucleos(t)ide analogue therapy

Wang T. et al, (2025), JHEP Reports, 7

Impact of SARS-CoV-2 vaccination in patients with vascular liver diseases: Observations from a VALDIG multicenter study

Perez-Campuzano V. et al, (2024), JHEP Reports, 6

Distinct Requirements for CD4+ T Cell Help for Immune Responses Induced by mRNA and Adenovirus-Vector SARS-CoV-2 Vaccines.

Yong L. et al, (2024), Eur J Immunol

Greater preservation of SARS-CoV-2 neutralising antibody responses following the ChAdOx1-S (AZD1222) vaccine compared with mRNA vaccines in haematopoietic cell transplant recipients.

Colton H. et al, (2024), Br J Haematol

Prospective cohort for early detection of liver cancer (Pearl): a study protocol.

Khanna K. et al, (2024), BMJ Open, 14

Corrigendum to ‘Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study’ [The Lancet Regional Health – Europe 35 (2023) 100747] (The Lancet Regional Health - Europe (2023) 35, (S2666776223001667), (10.1016/j.lanepe.2023.100747))

Evans RA. et al, (2024), The Lancet Regional Health - Europe, 44

Cost-Effectiveness of Hepatocellular Carcinoma Surveillance Strategies in Patients With Compensated Liver Cirrhosis in the United Kingdom.

Garay OU. et al, (2024), Value Health

Immunogenicity of COVID-19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapy.

Lim YJ. et al, (2024), Br J Haematol

Effect of Prior ChAdOx1 COVID-19 Immunisation on T-Cell Responses to ChAdOx1-HBV.

Davis C. et al, (2024), Vaccines (Basel), 12

Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial.

Goodyear CS. et al, (2024), Lancet Rheumatol

Vascular adhesion protein-1 blockade in primary sclerosing cholangitis: Open-label, multicenter, single-arm, phase II trial.

Hirschfield GM. et al, (2024), Hepatol Commun, 8

Safety, tolerability, viral kinetics, and immune correlates of protection in healthy, seropositive UK adults inoculated with SARS-CoV-2: a single-centre, open-label, phase 1 controlled human infection study.

Jackson S. et al, (2024), Lancet Microbe

Obesity Differs from Diabetes Mellitus in Antibody and T Cell Responses Post COVID-19 Recovery.

Ali M. et al, (2024), Clin Exp Immunol

Analysis of primary care electronic health record data of people living with hepatitis B virus: infection and hepatocellular carcinoma risk associated with socio-economic deprivation.

Campbell C. et al, (2024), Public Health, 226, 215 - 227

Immune responses and clinical outcomes after COVID-19 vaccination in patients with liver disease and liver transplant recipients.

Murray SM. et al, (2024), J Hepatol, 80, 109 - 123

HepFREEPak: protocol for a multi-centre, prospective observational study examining efficacy and impact of current therapies for the treatment of hepatitis C in Pakistan and reporting resistance to antiviral drugs: study protocol.

Arif A. et al, (2023), BMC Public Health, 23

Phylogenetic Analysis of Hepatitis C Virus Infections in a Large Belgian Cohort Using Next-Generation Sequencing of Full-Length Genomes.

Christensen KT. et al, (2023), Viruses, 15

Classification of virologic trajectories during nucleos/tide analogue treatment of hepatitis B virus (HBV) infection

Wang T. et al, (2023)

Correction to: Patient Biochemistry and Treatment Need in Chronic Hepatitis B Virus Infection Across Three Continents: Retrospective Cross-Sectional Cohort Studies.

Gillespie IA. et al, (2023), Infect Dis Ther, 12, 2533 - 2534

HBV001: Phase I study evaluating the safety and immunogenicity of the therapeutic vaccine ChAdOx1-HBV.

Cargill T. et al, (2023), JHEP Rep, 5

Load More

1
2
3
4
5
6
7
...
»